Clever Leaves Holdings Inc.: insider trades · United States · SEC (Form 4)

About Clever Leaves Holdings Inc.

Clever Leaves Holdings Inc. is a specialty cannabinoid company that was listed on the U.S. NASDAQ under ticker CLVR, operating in the United States and built around medically oriented cannabis and hemp assets. From an equity-research perspective, this is not a broad consumer cannabis story; it is a regulated, cross-border pharmaceutical-adjacent platform that historically focused on cultivation, extraction, processing, and export of medical cannabis products. The company emerged from the combination of Clever Leaves and a SPAC transaction completed in December 2020, and its corporate structure has been shaped by a mix of Latin American operations, European compliance ambitions, and limited U.S.-based wellness activities distinct from U.S. cannabis cultivation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1819615/000121390022015628/posam2022a1_cleverleaves.htm?utm_source=openai)) Clever Leaves’ core business has been the production of medical cannabis and hemp-derived inputs, including dried flower, extracts, API-like intermediates, and finished or semi-finished products for regulated markets. The company positioned itself as a vertically integrated supplier, seeking to combine large cultivation capacity with pharma-grade quality control. Its competitive pitch centered on lower-cost production in Colombia and on GMP-related certifications that were intended to support exports into tightly regulated jurisdictions. The company’s annual report for 2023 highlighted significant Colombian cultivation and extraction capabilities and noted certifications relevant to medical markets, including EU-GMP-related re-certification and Australian GMP certification for facilities in Colombia. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1819615/000181961524000031/clvr-20231231.htm?utm_source=openai)) Geographically, Clever Leaves’ strategy historically spanned Latin America and Europe, with sales and distribution ambitions extending to markets such as Australia and other medical-cannabis jurisdictions. It also maintained a U.S. wellness business, while explicitly stating that it did not cultivate or sell cannabis in the United States. Over time, however, the operating footprint was materially reduced. The company scaled back extraction capacity, wound down its Portuguese operations, and later sold its EU-GMP certified facility assets in Portugal to Curaleaf in July 2023. Those actions indicate a sharp retrenchment from the original global expansion thesis. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1819615/000181961524000031/clvr-20231231.htm?utm_source=openai)) The most important recent corporate event was the April 24, 2024 board approval to voluntarily delist from NASDAQ and deregister the common shares and warrants under the Exchange Act, a move aimed at cutting the costs and administrative burden of being a public reporting company. For investors in France, Belgium, and Switzerland, that is a critical signal: CLVR’s public-market profile changed materially in 2024, and the company moved away from the standard NASDAQ disclosure framework. In practical terms, Clever Leaves remains a highly specialized, high-risk cannabis/pharma-adjacent issuer whose recent history has been dominated by restructuring, asset rationalization, and a shrinking public-market footprint. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1819615/000121390024036656/ea0204744-8k_clever.htm?utm_source=openai))